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BACKGROUND: Gamma glutamyltransferase (GGT) was reported recently to be associated with inflammation, oxidative stress and increased 
amino acid. However, role of GGT in insulin resistance 
pathomechanism is not exactly known. Therefore 
correlation of GGT with inflammation, oxidative stress and 
elevated amino acid, in men with central obesity need to be 
confirmed. 
METHODS: A cross-sectional study was designed. 
Men with central obesity were recruited and selected. 
Anthropometric parameters, creatinine, hs-CRP, fasting 
glucose, fasting insulin, glutathione peroxidase (GPx) 
activity, GGT, plasma total cysteine (tCys) and fatty liver 
were measured. Subjects were then divided in 4 groups 
based on waist circumference (WC) and fatty liver: Group 
I: WC ≤100 cm, without fatty liver; Group II: WC ≤100 cm, 
with fatty liver; Group III: WC >100 cm, without fatty liver; 
Group IV: WC >100 cm, with fatty liver. All biochemical 
characteristics in each group were then statistically analyzed.
RESULTS: Seventy-two men with central obesity were 
selected. Numbers of subjects in each group were: Group I: 
n=33; Group II: n=5; Group III: n=17; Group IV: n=17. We 
found significant difference of HOMA-IR between Group I 
and IV, significant correlation between GGT and HOMA-
IR, and significant negative correlation between tCys with 
HOMA-IR in Group IV.
CONCLUSION: GGT was significantly correlated with 
HOMA-IR in men with WC >100 cm and fatty liver. Further 
investigation with more subjects is necessary to determine 
LATAR BELAKANG: Gamma glutamyltransferase (GGT) dilaporkan berhubungan dengan inflamasi, stres oksidatif dan peningkatan asam amino. 
Akan tetapi peran GGT pada patomekanisme resistensi 
insulin belum jelas. Oleh karena itu korelasi GGT dengan 
inflamasi, stres oksidatif dan peningkatan asam amino pada 
pria dengan obesitas sentral masih perlu dikonfirmasi.
METODE: Penelitian potong lintang didesain. Pria 
dengan obesitas sentral direkrut dan diseleksi. Parameter 
antropometrik, kreatinin, hs-CRP, glukosa puasa, insulin 
puasa, aktivitas glutathione peroxidase (GPx), GGT, 
plasma total cysteine (tCys) dan perlemakan hati dilakukan 
pengukuran. Subyek kemudian dibagi menjadi 4 kelompok 
berdasarkan lingkar pinggang (LP) dan perlemakan hati: 
Grup I: LP ≤100 cm, tanpa perlemakan hati; Grup II: LP 
≤100 cm, dengan perlemakan hati; Grup III: LP >100 cm, 
tanpa perlemakan hati; Grup IV: LP >100 cm, dengan 
perlemakan hati. Kemudian semua karakteristik biokimia 
pada setiap grup dilakukan analisa statistik.
HASIL: Tujuh puluh dua pria dengan obesitas sentral 
diseleksi. Jumlah subyek pada masing-masing  grup adalah: 
Grup I: n=33; Grup II: n=5; Grup III: n=17; Grup IV: n=17. 
Kami menemukan perbedaan bermakna pada HOMA-IR 
antara Grup I dan IV, korelasi bermakna antara GGT dan 
HOMA-IR, serta korelasi negatif bermakna antara tCys 
dengan HOMA-IR pada Grup IV.
KESIMPULAN: GGT berkorelasi bermakna dengan 
HOMA-IR pada pria dengan LP >100 cm dan perlemakan 
hati. Penelitian lebih lanjut dengan subyek yang lebih 
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clear GGT cut-off to distinguish subjects with fatty liver and 
insulin resistance.
KEYWORDS: GGT, hs-CRP, GPx, tCys, HOMA-IR, 
insulin resistance
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banyak dibutuhkan agar dapat menentukan cut-off GGT 
secara jelas sehingga dapat membedakan subyek dengan 
perlemakan hati dan resisten insulin.
KATA KUNCI: GGT, hs-CRP, GPx, tCys, HOMA-IR, 
resistensi insulin
Subjects
Men with central obesity in Malang and Denpasar, aged 30-
60 years old, WC ≥90 cm, were recruited. Medical records 
were obtained. Subjects with hs-CRP > 10 mg/L, estimated 
glomerular filtration rate (eGFR) <60 mL/minute/1.73m2, 
hepatitis B and C, cirrhosis, malignancy, vegetarian, 
smoking habit, and intake of alcohol, supplement, 
antioxidant or hepatotoxicity drugs, were excluded. This 
study was approved by the Ethics Committee of Hasanuddin 
University Faculty of Medicine (UH13020059), and written 
informed consent was obtained from each subject.
Blood collection and biochemical analyses 
Venous blood samples were collected in the morning 
after 10-12 hours fasting, in plain, EDTA-contained and 
heparin-contained vacutainers. Plain and EDTA-contained 
vacutainers were  then centrifuged. 
 Resulted serum in plain vacutainer was collected and 
examined for fasting glucose, hs-CRP, creatinine, GGT 
and fasting insulin. For fasting glucose assay, GLUC3 kit 
(Roche Diagnostics GmbH, Mannheim, Germany) was 
used. For hs-CRP assay, CRPHS kit (Roche Diagnostics 
GmbH, Mannheim, Germany) was used. For creatinine 
assay, Creatinine plus ver.2 kit (Roche Diagnostics GmbH, 
Mannheim, Germany) was used. Autoanalyzer Cobas 
Integra 400 (Roche Diagnostics, Rotkreuz, Switzerland) 
was applied for fasting glucose, hs-CRP and creatinine 
assays.
 For GGT assay, GGT kit (Bayer Healthcare, 
Tarrytown, NY) and Autoanalyzer ADVIA 1800 (Siemens 
Medical Solutions Diagnostics, Tarrytown, NY) were used. 
For fasting insulin assay, Immulite 2000 Insulin kit (Siemens 
Introduction
Methods
Obesity is one of metabolic syndrome major criteria, 
which related with cardiometabolic diseases, such as 
type 2 diabetes mellitus, hypertension and coronary heart 
disease.(1) Increased prevalence of obesity was closely 
related to prevalence of metabolic syndrome and increased 
cardiometabolic disease risk. Therefore, it is important to 
develop biomarker for observing progression from central 
obesity to metabolic syndrome. 
 Gamma glutamyltransferase (GGT), mostly 
produced in liver(2), involved in intracellular homeostasis 
to resynthesis glutathione (GSH) by maintaining the 
availability of cysteine(3). Initially, GGT was known as a 
biomarker for liver disease or excessive alcohol intake, but 
recent reports showed that GGT could be an independent 
predictor of risk cardiometabolic disease.(4,5) Elevated 
GGT in subject with metabolic syndrome was reported to 
have a correlation with central obesity, resistance insulin 
and hepatic steatosis.(6) However, role of GGT in insulin 
resistance pathomechanism is not exactly known. Several 
studies showed correlation  of GGT with inflammation, 
oxidative stress(7-9) and elevated amino acid(10), that could 
be related with insulin resistance pathomechanism(8,11).
 C-reactive Protein (CRP), synthesized in the liver, is 
not only an acute phase protein, but also a marker of chronic 
low grade inflammation.(12) Several studies showed 
association of elevated CRP level with cardiovascular 
disease(13) and with abdominal obesity.(14) Meanwhile, 
glutathione peroxidase (GPx) that involves in detoxification 
of H
2
O
2
 and lipid peroxide by catalyzing GSH, showes its 
important role to defense oxidative stress.(15) Lower GPx 
level was reported in obese patient than healthy subject.(14) 
Cysteine is an essential proteinogenic amino acid containing 
sulfur. Plasma total cysteine (tCys) contains all forms of 
cysteine in the circulation including free form, disulfide 
and cysteine-bound albumin.(16) tCys was reported to be 
associated with homeostatic model assessment insulin 
resistance index (HOMA-IR).(11)
 To our current interest in finding a possible insulin 
resistance pathomechanism, we examined correlation of 
GGT with inflammation (high sensitivity CRP (hs-CRP)), 
oxidative stress (GPx) and elevated amino acid (tCys), in 
men with central obesity.
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Healthcare Diagnostics, Tarrytown, NY) and Immulite 2000 
(Siemens Medical Solutions Diagnostics, Flanders, NJ) 
were used.
 Resulted plasma in EDTA-contained vacutainer was 
collected and examined for tCys by using ClinRep Complete 
kit for Homocysteine in plasma (Recipe Chemicals & 
Instruments GmbH, Munich, Germany) and Agilent 1100 
HPLC (Agilent Technologies, Waldbronn, Germany).
 Venous blood in heparin-contained vacutainer 
was collected and examined for GPx activity by using 
Glutathione Peroxidase kit (Randox Laboratories Limited, 
Crumlin, County Antrim) and Autoanalyzer ADVIA 1800 
(Siemens Medical Solutions Diagnostics, Tarrytown, NY).
Each assay was performed according to the protocol 
provided in each kit. Fatty liver check was performed with 
abdominal ultrasonography (Logic 3 Pro, General Electric 
Co, Milwaukee, WI). Fatty liver and its grades (I, II and III) 
were determined by a radiologist.
Statistical analysis 
 Statistical analysis was performed using IBM SPSS 
for Windows version 19.0 (IBM Corp., Armonk, NY). All 
Anthropometric and biochemical characteristics of 72 men 
with central obesity, aged 42.4±8.7 (range: 30-60 years) 
and the mean of WC was 100.3±6.9 (range: 90-128 cm), 
were obtained and shown in Table 1. Among the subjects 
with WC ≤100 cm, we found 5 subjects with fatty liver (3 
subjects with fatty liver grade I and 2 subjects with fatty 
liver grade II). Meanwhile among the subjects with WC 
>100 cm, we found 17 subjects with fatty liver (4 subjects 
with fatty liver grade I, 5 subjects with fatty liver grade II, 
and 8 subjects with fatty liver grade III). All Subjects were 
then grouped based on WC and fatty liver: Group I: WC 
≤100 cm, without fatty liver, n=33; Group II: WC ≤100 cm, 
with fatty liver, n=5; Group III: WC >100 cm, without fatty 
liver, n=17; Group IV: WC >100 cm, with fatty liver, n=17.
Results
Variable Mean±SD Median Min Max
     Age (years) 42.40±8.70 41.50 30 60
     WC (cm) 100.30±6.90 99 90 128
     Height (cm) 167.90±6.10 167.30 154 181
     Weight (Kg) 80.30±10.50 78.20 63 125
     BMI (Kg/m2) 28.40±2.80 27.90 24 39
     Hb (g/dL) 15.70±1.00 15.60 14 18
     GGT (U/L) 44.20±12.80 35 14 178
     Fasting Glucose (mg/dL) 97.60±26.80 90.50 77 235
     Fasting Insulin (uIU/mL) 13.60±14.50 9.60 4 100
     hs-CRP (mg/L) 2.10±1.60 1.70 0.36 9.30
     Creatinine (mg/dL) 0.94±0.10 0.90 0.70 1.30
     eGFR (minute/1.73m2) 98.10±15.30 100 64 128
     GPx activity (U/gHb) 48.10±13.40 46.30 28 107
     tCys (µmol/L) 250.20±44.80 242 175.70 362.30
     HOMA-IR 3.20±3.40 2.30 0.80 24.70
Table 1. Anthropometric and biochemical characteristics of subjects
BMI: body mass index, SD: standard deviation.
values are expressed as mean ± standard deviation (SD), 
unless otherwise specified. Mann Whitney and Spearman 
analyses were used at a significance level of p≤0.05.
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Table 3. Correlation of GGT, hs-CRP, GPx activity, tCys and HOMA-IR in each group.
r p  (*) r p  (*) r p  (*) r p  (*) r p  (*)
     GGT with hs-CRP 0.129 0.140 0.096 0.297 1.000 0.000 0.073 0.391 0.068 0.398
     GGT with GPx -0.081 0.250 -0.172 0.169 0.100 0.436 -0.326 0.101 0.307 0.116
     GGT with t-Cys -0.121 0.156 -0.183 0.153 0.700 0.094 -0.129 0.311 -0.301 0.120
     GGT with HOMA-IR 0.179 0.066 -0.018 0.460 0.100 0.436 0.018 0.472 0.604 0.005
     hs-CRP with HOMA-IR 0.134 0.131 0.182 0.155 0.100 0.436 0.124 0.318 -0.027 0.459
     GPx activity with HOMA-IR -0.121 0.156 -0.219 0.111 0.200 0.374 0.167 0.261 0.022 0.467
     tCys with HOMA-IR -0.129 0.141 -0.093 0.304 0.600 0.142 -0.098 0.354 -0.415 0.049
G IV (n=17)
Correlation between
Total (n=72) G I (n=33) G II (n=5) G III (n=17)
*: Spearman correlation analysis; G I: Group I, G II: Group II, G III: Group III, G IV: Group IV; Significant p values were marked in bold.
Mean ± SD G I & G II G I & G III G I & G IV G II & G III G II & G IV G III & G IV
l (n=33) 42.3±30.7 0.492 0.246 0.276 0.348 0.348 0.459
ll (n=5) 36.6±15.3
lll (n=17) 42.9±21.7
IV (n=17) 49.6±39.5
l (n=33) 2.1±1.9 0.423 0.500 0.062 0.453 0.136 0.046
ll (n=5) 1.7±1.4
lll (n=17) 1.7±0.9
IV (n=17) 2.6±1.6
l (n=33) 50.1±11.6 0.018 0.464 0.009 0.019 0.145 0.021
ll (n=5) 38.9±6.9
lll (n=17) 53.2±17.7
IV (n=17) 41.8±7.7
l (n=33) 250.9±51.1 0.341 0.403 0.360 0.306 0.164 0.309
ll (n=5) 258.1±49.0
lll (n=17) 253.4±45.2
IV (n=17) 243.2±31.5
l (n=33) 2.8±2.9 0.341 0.166 0.017 0.184 0.074 0.172
ll (n=5) 2.1±1.2
lll (n=17) 3.9±2.7
IV (n=17) 3.7±2.0
     HOMA-IR
Variable Group
     GGT
p  (*)
     hs-CRP
     GPx activity
     tCys
Table 2. Correlation of GGT, hs-CRP, GPx activity, tCys and HOMA-IR in different groups.
*: Mann Whitney analysis; G I: Group I, G II: Group II, G III: Group III, G IV: Group IV; Significant p values were marked in bold.
 105
Correlation of GGT, GPx, hs-CRP and tCys (Ritawaty)Indones  Biomed J.  2013; 5(2): 101-6DOI: 10.18585/inabj.v5i2.58
Discussion
Conclusion
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Combination of obesity with less physical activity 
and excessive caloric consumption would induce insulin 
resistance.(17) Most subjects with central obesity have 
insulin resistance characteristic, but not all obese would 
have insulin resistance syndrome.(18) GGT was reported 
to be associated with insulin resistance with markers of 
fasting insulin and HOMA-IR.(3,19-21) In our current 
study, we found that GGT and HOMA-IR were significantly 
correlated in Group IV. Therefore, our results confirmed the 
previous reports, suggesting that GGT could be associated 
with insulin resistance, due to adiposity and ectopic fat in the 
liver in obese subjects.(22) In addition, our ultrasonographic 
results showed that subjects with higher fatty liver grade 
were found in Group IV comparing to Group II.
 There were not significant correlations of GGT 
and hs-CRP, GGT and GPx, GGT and tCys, hs-CRP and 
HOMA-IR, GPx and HOMA-IR, since we found that our 
subject were included in hs-CRP middle risk (1.00-3.00 
mg/L) and reference range of GPx activity (27.5-73.6 U/
gHb), suggesting that there was a homeostatic mechanism. 
Insulin resistance-associated obesity with excessive release 
of non-esterified fatty acid (NEFA) from adipose tissue 
into plasma and accumulated in liver, can impair insulin 
sensitivity.(1,3) In addition, a study conducted in children 
and adolescent showed positive association between tCys-
NEFA and tCys-HOMA-IR. Subjects with high tCys have 
double-risk of insulin resistance.(11) But interestingly, in 
our current study, we found a significant negative correlation 
between tCys with HOMA-IR in Group IV. We assume that 
cysteine dioxygenase homeostasis mechanism might be 
involved, Cysteine dioxygenase has been reported to have 
an important role in controlling tCys level.(11) Additionally 
since Group IV consist of subject with non-alcoholic fatty 
liver disease, which means they have lower concentration of 
total glutathione as a results of oxidant stress, and also and 
lower concentrations of cysteine-glutathione disulfide. This 
may results the false negative correlation between tCys with 
HOMA-IR.
In summary, GGT was significantly positive-correlated with 
HOMA-IR in men with WC >100 cm and fatty liver. Further 
investigation with more subjects is necessary to determine 
clear GGT cut-off to distinguish subjects with fatty liver and 
insulin resistance.
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